Tocilizumab inhibits structural joint damage, improves physical function, and increases DAS28 remission rates in RA patients who respond inadequately to methotrexate: the LITHE study

Category Primary study
ConferenceEULAR 2009. Published in: Ann Rheum Dis
Year 2009
This article has no abstract
Epistemonikos ID: bd98f0bb0a0b66cb0fd1a34cb00b6c07a1a09720
First added on: Oct 25, 2017